PI3K Inhibition for Squamous Cell Head and Neck Carcinoma

被引：5
|
作者：
Desilets, Antoine [1 ,2 ]
Soulieres, Denis [1 ]
机构：
[1] Ctr Hosp Univ Montreal CHUM, Pavillon C,1000 Rue St Denis, Montreal, PQ H2X 0C1, Canada
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER JOURNAL | 2022年 / 28卷 / 05期
关键词：
Head and neck squamous cell carcinoma; PI3K inhibitors; targeted therapy; PHOSPHOINOSITIDE 3-KINASE INHIBITOR; I DOSE-ESCALATION; BUPARLISIB BKM120; PACLITAXEL; RECURRENT; CHEMOTHERAPY; COMBINATION; EXPRESSION; RECEPTOR; NIVOLUMAB;
D O I：
10.1097/PPO.0000000000000618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in most head and neck squamous cell carcinomas, making it a prized target for targeted therapy development. Multiple PI3K inhibitors have been studied in early phase trials, with unfavorable risk-benefit ratios in molecularly unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, shows promising efficacy in combination with paclitaxel for advanced head and neck squamous cell carcinoma. Results of the phase III BURAN trial are awaited.
引用
收藏
页码：369 / 376
页数：8
相关论文
共 50 条
  • [21] CAF-secreted COL5A2 activates the PI3K/AKT pathway to mediate erlotinib resistance in head and neck squamous cell carcinoma
    Guo, Yibo
    Chen, Mingtao
    Yang, Jie
    Zhou, Wenkai
    Feng, Guanying
    Wang, Yang
    Ji, Tong
    Zhang, Yu
    Liu, Zheqi
    ORAL DISEASES, 2025, 31 (02) : 376 - 386
  • [22] Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas
    Garcia-Carracedo, Dario
    Angeles Villaronga, M.
    Alvarez-Teijeiro, Saul
    Hermida-Prado, Francisco
    Santamaria, Inigo
    Allonca, Eva
    Suarez-Fernandez, Laura
    Victoria Gonzalez, M.
    Balbin, Milagros
    Astudillo, Aurora
    Martinez-Camblor, Pablo
    Su, Gloria H.
    Pablo Rodrigo, Juan
    Maria Garcia-Pedrero, Juana
    ONCOTARGET, 2016, 7 (20) : 29780 - 29793
  • [23] Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro
    Brands, Roman C.
    Knierim, Luise M.
    De Dono, Francesco
    Steinacker, Valentin
    Hartmann, Stefan
    Seher, Axel
    Kuebler, Alexander C.
    Mueller-Richter, Urs D. A.
    ONCOLOGY REPORTS, 2017, 38 (03) : 1877 - 1885
  • [24] Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma
    Shi, Meng-wen
    Huang, Jing
    Sun, Yu
    CURRENT MEDICAL SCIENCE, 2023, 43 (02) : 213 - 222
  • [25] Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck
    Gold, Kathryn A.
    Lee, Ho-Young
    Kim, Edward S.
    CANCER, 2009, 115 (05) : 922 - 935
  • [26] Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition
    Young, Natalie R.
    Liu, Jing
    Pierce, Carolyn
    Wei, Tai-Fen
    Grushko, Tatyana
    Olopade, Olufunmilayo I.
    Liu, Wanqing
    Shen, Christine
    Seiwert, Tanguy Y.
    Cohen, Ezra E. W.
    MOLECULAR ONCOLOGY, 2013, 7 (03) : 359 - 368
  • [27] DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways
    Katase, Naoki
    Nishimatsu, Shin-Ichiro
    Yamauchi, Akira
    Yamamura, Masahiro
    Fujita, Shuichi
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 54 (03) : 1021 - 1032
  • [28] Nasopharyngeal carcinoma with non-squamous phenotype may be a variant of nasopharyngeal squamous cell carcinoma after inhibition of EGFR/PI3K/AKT/mTOR pathway
    Wang, Jiahe
    Shang, Yifan
    Wang, Yujiao
    Li, Ye
    Wang, Lei
    Huang, Sixia
    Lyu, Xinquan
    HISTOLOGY AND HISTOPATHOLOGY, 2024, 39 (05) : 647 - 657
  • [29] Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2
    Keysar, Stephen B.
    Le, Phuong N.
    Miller, Bettina
    Jackson, Brian C.
    Eagles, Justin R.
    Nieto, Cera
    Kim, Jihye
    Tang, Binwu
    Glogowska, Magdalena J.
    Morton, J. Jason
    Padilla-Just, Nuria
    Gomez, Karina
    Warnock, Emily
    Reisinger, Julie
    Arcaroli, John J.
    Messersmith, Wells A.
    Wakefield, Lalage M.
    Gao, Dexiang
    Tan, Aik-Choon
    Serracino, Hilary
    Vasiliou, Vasilis
    Roop, Dennis R.
    Wang, Xiao-Jing
    Jimeno, Antonio
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (01):
  • [30] The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review
    Ghanizada, Mustafa
    Jakobsen, Kathrine Kronberg
    Gronhoj, Christian
    von Buchwald, Christian
    ORAL ONCOLOGY, 2019, 90 : 67 - 73
12345